Modulating amygdala responses to emotion: Evidence from pharmacological fMRI

Neuropsychologia

Volumn 49, Issue 4, 2011, Pages 706-717

  Patin, Alexandra ^a   Hurlemann, René ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Amygdala; Drug; Emotion; FMRI; Healthy; Human; Pharmacological

Indexed keywords

APREPITANT; ARGIPRESSIN; CITALOPRAM; CLOMIPRAMINE; CYCLOSERINE; DEXAMPHETAMINE; DOPAMINE; ESCITALOPRAM; FLUVOXAMINE; HYDROCORTISONE; LEVODOPA; LORAZEPAM; NEUROKININ 1 RECEPTOR; NORADRENALIN; OXYTOCIN; PLACEBO; PROPRANOLOL; REBOXETINE; SULTOPRIDE; TESTOSTERONE; 4 AMINOBUTYRIC ACID; ANTIBIOTIC AGENT; DEXTRO 4 AMINO 3 ISOXAZOLIDONE; GLUTAMIC ACID; MONOAMINE; SEROTONIN; UNCLASSIFIED DRUG; VASOPRESSIN;

AKATHISIA; AMYGDALOID NUCLEUS; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BRAIN FUNCTION; CHEMOTHERAPY INDUCED EMESIS; COGNITION; DRUG ABSORPTION; DRUG ACTIVATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESPONSE; DYSTONIA; EMOTION; FACIAL EXPRESSION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GABAERGIC SYSTEM; HUMAN; MAJOR DEPRESSION; MONOAMINERGIC SYSTEM; NARCOLEPSY; NEUROMODULATION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; OUTCOME ASSESSMENT; PARKINSON DISEASE; PASSIVE AGGRESSIVE PERSONALITY DISORDER; PEPTIDERGIC NERVOUS SYSTEM; POSTTRAUMATIC STRESS DISORDER; REPEATED DRUG DOSE; SEROTONINERGIC SYSTEM; SEXUAL DYSFUNCTION; SINGLE DRUG DOSE; SOCIAL AVOIDANCE BEHAVIOR; TARDIVE DYSKINESIA; TREATMENT RESPONSE; TREMOR; WITHDRAWAL SYNDROME; BEHAVIOR DISORDER; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DOPAMINERGIC SYSTEM; DRUG DOSE COMPARISON; DRUG MECHANISM; HEART DISEASE; HORMONE ACTION; NEUROPHARMACOLOGY; NEUROTRANSMISSION; NORADRENERGIC SYSTEM; PHARMACOLOGICAL STIMULATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANQUILIZING ACTIVITY;

AMYGDALA; BRAIN MAPPING; EMOTIONS; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROPHARMACOLOGY;

EID: 79952624719     PISSN: 00283932     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropsychologia.2010.10.004     Document Type: Article

References (105)

1. Abercrombie H.C., Kalin N.H., Thurow M.E., Rosenkranz M.A., Davidson R.J. Cortisol variation in humans affects memory for emotionally laden and neutral information. Behavioral Neuroscience 2003, 117:505-516.
2. Aggleton J.P. The amygdala: A functional analysis 2000, Oxford University Press, Oxford.
3. Alexander J.K., Hillier A., Smith R.M., Tivarus M.E., Beversdorf D.Q. Beta-adrenergic modulation of cognitive flexibility during stress. Journal of Cognitive Neuroscience 2007, 19:468-478.
4. Amunts K., Kedo O., Kindler M., Pieperhoff P., Mohlberg H., Shah N.J., et al. Cytoarchitectonic mapping of the human amygdala, hippocampal region and entorhinal cortex: Intersubject variability and probability maps. Anatomy and Embryology 2005, 210:343-352.
5. Anderson I.M., Del-Ben C.M., Mckie S., Richardson P., Williams R., Elliot R., et al. Citalopram modulation of neuronal responses to aversive face emotions: A functional MRI study. Neuroreport 2007, 18:1351-1355.
6. Andrade L., Caraveo-Anduaga J.J., Berglund P., Bijl R.V., De Graaf R., Vollebergh W., et al. The epidemiology of major depressive episodes: Results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. International Journal of Methods in Psychiatric Research 2003, 12:3-21.
7. Arce E., Simmons A.N., Lovero K.L., Stein M.B., Paulus M.P. Escitalopram effects on insula and amygdala BOLD activation during emotional processing. Psychopharmacology 2008, 196:661-672.
8. Aston-Jones G., Cohen J.D. An integrative theory of locus coeruleus-norepinephrine function: Adaptive gain and optimal performance. Annual Review of Neuroscience 2005, 28:403-540.
9. Barbas H. Anatomic basis of cognitive-emotional interactions in the primate prefrontal cortex. Neuroscience & Biobehavioral Reviews 1995, 19:449-510.
10. Benkert O., Hippius H. Kompendium der Psychiatrischen Pharmakotherapie 2007, Springer Medizin Verlag Heidelberg, Heidelberg, Germany.
11. Berridge C.W., Waterhouse B.D. The locus coeruleus-noradrenergic system: Modulation of behavioral state and state-dependent cognitive processes. Brain Research Reviews 2003, 42:33-84.
12. Bigos K.L., Pollock B.G., Aizenstein H.J., Fisher P.M., Bies R.R., Hariri A.R. Acute 5-HT reuptake blockade potentiates human amygdala reactivity. Neuropsychopharmacology 2008, 33:3221-3225.
13. Bliss T.V., Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. The Journal of Physiology 1973, 232:331-356.
14. Bonassi S., Au W.W. Biomarkers in molecular epidemiology studies for health risk prediction. Mutation Research 2002, 511:73-86.
15. Brantigan C.O., Brantigan T.A., Joseph N. Effect of beta blockade and beta stimulation on stage fright. American Journal of Medicine 1982, 72:88-94.
16. Britton J.C., Gold A.L., Feczko E.J., Rauch S.L., Williams D., Wright C.I. d-Cycloserine inhibits amygdala responses during repeated presentations of faces. CNS Spectrums 2009, 12:600-605.
17. Brockhaus H. Zur normalen und pathologischen Anatomie des Mandelkerngebietes. Journal für Psychologie und Neurologie 1938, 49:1-136.
18. Brockhaus H. Die Cyto- und Myeloarchitektonik des Cortex claustralis und des Claustrum beim Menschen. Journal für Psychologie und Neurologie 1940, 49:249-347.
19. Buffalari D.M., Grace A.A. Noradrenergic modulation of basolateral amygdala neuronal activity: Opposing influences of alpha-2 and beta receptor activation. Journal of Neuroscience 2007, 27:12358-12366.
20. Chenu F., Guiard G.P., Bourin M., Gardier A.M. Antidepressant-like activity of selective serotonin reuptake inhibitors combined with a NK1 receptor antagonist in the mouse forced swimming test. Behavioral Brain Research 2006, 172:256-263.
21. Czock D., Keller F., Rasche F.M., Haussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clinical Pharmacokinetics 2005, 44:61-98.
22. Davis M., Ressler K., Rothbaum B.O., Richardson R. Effects of d-cycloserine on extinction: Translation from preclinical to clinical work. Biological Psychiatry 2006, 60:369-375.
23. de Almeida J.R., Phillips M.L., Cerqueira C.T., Zilberman M., Lobo D., Henna E., et al. Neural activity changes to emotional stimuli in healthy individuals under chronic use of clomipramine. Journal of Psychopharmacology 2009, 24:1165-1174.
24. Del-Ben C.M., Deakin J.F.W., Mckie S., Delvai N.A., Williams S.R., Elliott R., et al. The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: An fMRI study. Neuropsychopharmacology 2005, 30:1724-1734.
25. Delaveau P., Salgado-Pineda P., Micallef-Roll J., Blin O. Amygdala activation modulated by levodopa during emotional recognition processing in healthy volunteers: A double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology 2007, 27:692-697.
26. Delaveau P., Salgaado-Pineda P., Wicker B., Micallef-Roll J., Blin O. Effect of levodopa on healthy volunteers' facial emotion perception: An fMRI study. Clinical Neuropharmacology 2005, 28:255-261.
27. Domes G., Lischke A., Berger C., Grossmann A., Hauenstein K., Heinrichs M., et al. Effects of intranasal oxytocin on emotional face processing in women. Psychoneuroendocrinology 2009, 35:83-93.
28. Domes G., Heinrichs M., Gläscher J., Büchel C., Braus D.F., Herpertz S.C. Oxytocin attenuates amygdala responses to emotional faces regardless of valence. Biological Psychiatry 2007, 62:1187-1190.
29. Ebner K., Rupniak N.M., Saria A., Singewald N. Substance P in the medial amygdala: Emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:4280-4285.
30. Fagerstrom K.O., Hugdahl K., Lundstrom N. Effect of beta-receptor blockade on anxiety with reference to the three-systems model of phobic behavior. Neurophsychobiology 1985, 13:187-193.
31. Faigel H.C. The effect of beta blockade on stress-induced cognitive dysfunction in adolescents. Clinical Pediatrics 1991, 30:441-445.
32. Ferguson J.N., Aldag J.M., Insel T.R., Young L.J. Oxytocin in the medial amygdala is essential for social recognition in the mouse. The Journal of Neuroscience 2001, 21:8278-8285.
33. Fitzgerald D.A., Angstadt M., Jelsone L.M., Nathan P.J., Phan K.L. Beyond threat: Amygdala reactivity across multiple expressions of facial affect. Neuroimage 2006, 30:1441-1448.
34. Gamer M., Zurowski B., Buechel C. Different amygdala subregions mediate valence-related and attentional effects of oxytocin in humans. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:9400-9405.
35. Gilles C., Luthringer R. Pharmacological models in healthy volunteers: Their use in the clinical development of psychotropic drugs. Journal of Psychopharmacology 2007, 21:272-282.
36. Goldman M., Marlow-O'Connor M., Torres I., Carter C.S. Diminished plasma oxytocin in schizophrenia patients with neuroendocrine dysfunction and emotional deficits. Schizophrenia Research 2008, 98:247-255.
37. Goldman N. Future directions in integration of biological and social theories. Presentation to the Chicago workshop on biological measures in population-based health and aging research 2007, June 12-14.
38. Goossens L., Kukolja J., Onur O.A., Fink G.R., Maier W., Griez E., et al. Selective processing of social stimuli in the superficial amygdala. Human Brain Mapping 2009, 30:3332-3338.
39. Green L., Fein D., Modahl C., Feinstein C., Waterhouse L., Morris M. Oxytocin and autistic disorder: Alterations in peptide forms. Biological Psychiatry 2001, 50:609-613.
40. Grillon C., Cordova J., Morgan C.A., Charney D.S., Davis M. Effects of beta-blocker propranolol on cued and contextual fear conditioning in humans. Psychopharmacology 2004, 175:342-352.
41. Hariri A.R., Mattay V.S., Tessitore A., Fera F., Smith W.G., Weinberger D.R. Dextroamphetamine modulates the response of the human amygdala. Neuropsychopharmacology 2002, 27:1036-1040.
42. Harmer C.J., Mackay C.E., Reld C.B., Cowen P.J., Goodwin G.M. Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biological Psychiatry 2006, 59:816-820.
43. Heimer L., de Olmos J.S., Alheid G.F., Pearson J., Sakamoto N., Shinoda K., et al. The human basal forebrain. Part II. The primate nervous system. Part III 1999, Elsevier, pp. 57-226.
44. Heinrichs M., von Dawans B., Domes G. Oxytocin, vasopressin, and human social behavior. Frontiers in Neuroendocrinology 2009, 30:548-557.
45. Hermans E., Ramsey N.F., van Honk J. Exogenous testosterone enhances responsiveness to social threat in the neural circuitry of social aggression in humans. Biological Psychiatry 2008, 63:263-270.
46. Honey G., Bullmore E. Human pharmacological MRI. Trends in Pharmacological Sciences 2004, 25:366-374.
47. Hood W.F., Compton R.P., Monahan J.B. d-Cycloserine: A ligand for the N-methyl-d-aspartate coupled glycine receptor has partial agonist characteristics. Neuroscience Letters 1989, 98:91-95.
48. Huber D., Veinante P., Stoop R. Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. Science 2005, 308:245-248.
49. Hurlemann R. Noradrenergic-glucococorticoid mechanisms in emotion-induced amnesia: From adaptation to disease. Psychopharmacology (Berlin) 2008, 197:13-23.
50. Hurlemann R., Matusch A., Klingmüller D., Kölsch H., Maier W., Dolan R.J. Emotion-induced retrograde amnesia varies as a function of noradrenergic-glucocorticoid effects. Psychopharmacology (Berlin) 2007, 194:261-269.
51. Hurlemann R., Walter H., Rehme A.K., Kukolja J., Santoro S.C., Schnell K., et al. Human amygdala activity is diminished by the beta-noradrenergic antagonist propranolol. Psychological Medicine 2010, 27:1-10.
52. Hurlemann R., Patin A., Onur O.A., Cohen M.X., Baumgartner T., Metzler S., et al. Oxytocin enhances amygdala-dependent, socially reinforced learning and emotional empathy in humans. The Journal of Neuroscience 2010, 30:4999-5007.
53. Inoue T., Nakagawa S., Izumi T., Kitaichi Y., Koyama T. Effect of combined treatment with noradrenaline and serotonin reuptake inhibitors on conditioned freezing. European Journal of Pharmacology 2006, 540:91-95.
54. Joels M. Corticosteroid effects in the brain: U-shape it. Trends in Pharmacological Sciences 2006, 27:244-250.
55. Kalisch R., Holt B., Petrovic P., De Martino B., Klöppel S., Büchel C., et al. The NMDA agonist d-cycloserine facilitates fear memory consolidation in humans. Cerebral Cortex 2009, 18:187-196.
56. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., et al. The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). The Journal of the American Medical Association 2003, 289:3095-3105.
57. Kirsch P., Esslinger C., Chen Q., Mier D., Lis S., Siddhanti S., et al. Oxytocin modulates neural circuitry for social cognition and fear in humans. The Journal of Neuroscience 2005, 25:11489-11493.
58. Kornischka J., Cordes J., Agelink M.W. 40 Years beta-adrenergic blockers in psychiatry. Fortschritte der Neurologie-Psychiatrie 2007, 75:199-210.
59. Kosfeld M., Heinrichs M., Zak P., Fischbacher U., Fehr E. Oxytocin increases trust in humans. Nature 2005, 435:673-676.
60. Kuhlmann J., Wensing G. The applications of biomarkers in early clinical drug development to improve decision-making processes. Current Clinical Pharmacology 2006, 1:185-191.
61. Kukolja J., Schlaepfer T.E., Keysers C., Klingmueller D., Maier W., Fink G.R., et al. Modeling a negative response bias in the human amygdala by noradrenergic-glucocorticoid interactions. The Journal of Neuroscience 2008, 28:12868-12876.
62. LaBar K.S., Crupain M.J., Voyvodic J.T., McCarthy G. Dynamic perception of facial affect and identity in the human brain. Cerebral Cortex 2003, 13:1023-1033.
63. Lang P.J., Bradley M.M., Cuthbert B.N. International affective picture system: Technical manual and affective ratings 1995, Center for Research in Psychophysiology, University of Florida, Gainsville, FL.
64. LeDoux J. The amygdala. Current Biology 2007, 17:R868-874.
65. Lee H.-J., Macbeth A.H., Pagani J.H., Scott Young W. Oxytocin: The great facilitator of life. Progress in Neurobiology 2009, 88:127-151.
66. Leppaenen J.M. Emotional information processing in mood disorders: A review of behavioral and neuroimaging findings. Current Opinion in Psychiatry 2006, 19:34-39.
67. Liu H.H., Milgrom P., Fiset L. Effect of a beta-adrenergic blocking agent on dental anxiety. Journal of Dental Research 1991, 70:1306-1308.
68. 1 receptor antagonism and the neural processing of emotional information in healthy volunteers. International Journal of Neuorpsychopharmacology 2009, 12:1261-1274.
69. McGaugh J.L. Memory - A century of consolidation. Science 2000, 287:248-251.
70. Meyer-Lindenberg A., Kolachana B., Gold B., Olsh A., Nicodemus K.K., Mattay V., et al. Genetic variants in AVPR1A linked to autism predict amygdala activation and personality traits in healthy humans. Molecular Psychiatry 2009, 14:968-975.
71. Miyata S., Shimoi T., Hirano S., Yamada N., Hata Y., Yoshikawa N., et al. Effects of serotonergic anxiolytics on the freezing behavior in the elevated open-platform test in mice. Journal of Pharmacological Sciences 2007, 105:272-278.
72. Modahl C., Green L., Fein D., Morris M., Waterhouse L., Feinstein C., et al. Plasma oxytocin levels in autistic children. Biological Psychiatry 1998, 43:270-277.
73. Murphy S.E., Norbury R., O'Sullivan U., Cowen P.J., Harmer C.J. Effect of a single dose of citalopram on amygdala response to emotional faces. The British Journal of Psychiatry 2009, 184:535-540.
74. Nephew B.C., Bridges R.S., Lovelock D.F., Byrnes E.M. Enhanced maternal aggression and associated changes in neuropeptide gene expression in multiparous rats. Behavioral Neuroscience 2009, 123:949-957.
75. Norberg M.M., Krystal J.H., Tolin D.F. A meta-analysis of d-cycloserine and the facilitation of fear extinction and exposure therapy. Biological Psychiatry 2008, 63:1118-1126.
76. Norbury R., Taylor M.J., Selvaraj S., Murphy S.E., Harmer C.J., Cowen P.J. Short-term antidepressant treatment modulates amygdala response to happy faces. Psychopharmacology 2009, 206:197-204.
77. Norbury R., Mackay C.E., Cowen P.J., Goodwin G.M., Harmer C.J. Short-term antidepressant treatment and facial processing. The British Journal of Psychiatry 2007, 190:531-532.
78. Onur O.A., Walter H., Schlaepfer T.E., Rehme A.K., Schmidt C., Keysers C., et al. Noradrenergic enhancement of amygdala responses to fear. Social Cognitive and Affective Neuroscience 2009, 4:119-126.
79. Onur O.A., Schlaepfer T.E., Kukolja J., Bauer A., Jeung H., Patin A., et al. The N-methyl-d-aspartate receptor co-agonist d-cycloserine facilitates declarative learning and hippocampal activity in humans. Biological Psychiatry 2010, 67:1205-1211.
80. Parker K.J., Kenna H.A., Zeitzer J.M., Keller J., Blasey C.M., Amico J.A., et al. Preliminary evidence that plasma oxytocin levels are elevated in major depression. Psychiatry Research 2010, 178:359-362.
81. Paulus M.P., Feinstein J.S., Castillo G., Simmons A.N., Stein M.B. Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotional processing. Archives of General Psychiatry 2005, 62:282-288.
82. Pezawas L., Meyer-Lindenberg A., Drabant E.M., Verchinski B.A., Munoz K.E., Kolachana B.S., et al. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: A genetic susceptibility mechanism for depression. Nature Neuroscience 2005, 8:828-834.
83. Pessoa L. On the relationship between emotion and cognition. Nature Reviews Neuroscience 2008, 9:148-158.
84. Phelps E.A. Human emotion and memory: Interactions of the amygdala and hippocampal complex. Current Opinion in Neurobiology 2004, 14:198-202.
85. Ravaris C.L., Friedman M.J., Hauri P.J., McHugo G.J. A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients. Journal of Clinical Psychopharmacology 1991, 11:344-350.
86. Rodriguez-Romaguera J., Sotres-Bayon F., Mueller D., Quirk G.J. Systemic propranolol acts centrally to reduce conditioned fear in rats without impairing extinction. Biological Psychiatry 2009, 15:887-892.
87. Roozendaal B., McEwen B.S., Chattarji S. Stress, memory and the amygdala. Nature Reviews Neuroscience 2009, 10:423-433.
88. Sergerie K., Chochol C., Armony J.L. The role of the amygdala in emotional processing: A quantitative meta-analysis of functional neuroimaging studies. Neuroscience & Biobehavioral Reviews 2008, 32:811-830.
89. Seymour B., Dolan R.J. Emotion, decision making, and the amygdala. Neuron 2008, 58:662-671.
90. Swanson L.W. The amygdala and its place in the cerebral hemisphere. Annals of the New York Academy of Sciences 2003, 985:174-184.
91. Swanson L.W., Petrovich G.D. What is the amygdala?. Trends in Neuroscience 1998, 21:323-331.
92. Stein J.L., Wiedholz L.M., Bassett D.S., Weinberger D.R., Zink C.F., Mattay V.S., et al. A validated netword of effective amygdala connectivity. Neuroimage 2007, 39:548.
93. Takahashi H., Yahata N., Koeda M., Takano A., Asai K., Suhara T., et al. Effects of dopaminergic and serotonergic manipulation on emotional processing: A pharmacological fMRI study. Neuroimage 2005, 27:991-1001.
94. Thompson L.T., Moskal J.R., Disterhoft J.F. Hippocampus-dependent learning facilitated by a monoclonal antibody or d-cycloserine. Nature 1992, 359:638-641.
95. Thompson R., Gupta S., Miller K., Mills S., Orr S. The effects of vasopressin on human facial responses related to social communication. Psychoneuroendocrinology 2004, 29:35-48.
96. Tyrer P. Current status of beta-blocking drugs in the treatment of anxiety disorders. Drugs 1988, 36:773-783.
97. Van der Gaag C., Minderaa R.B., Keysers C. The BOLD signal in the amygdala does not differentiate between dynamic facial expressions. Social Cognitive and Affective Neuroscience 2007, 2:93-103.
98. Van Stegeren A.H., Goekoop R., Everaerd W., Scheltens P., Barkhof F., Kuijer J.P.A., et al. Noradrenaline mediates amygdala activation in men and women during encoding of emotional material. Neuroimage 2005, 24:898-909.
99. Van Wingen G.A., Zylicz S.A., Pieters S., Mattern C., Verkes R.J., Buitelaar J.K., et al. Testosterone increases amygdala reactivity in middle-aged women to a young adulthood level. Neuropsychopharmacology 2009, 34:539-547.
100. Van Wingen G.A., Mattern C., Verkes R.V., Buitelaar J., Fernandez G. Testosterone reduces amygdala-orbitofrontal cortex coupling. Psychoneuroendocrinology 2010, 35:105-113.
101. Windischberger C., Lanzenberger R., Holik A., Spindelegger C., Stein P., Moser U., et al. Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: A randomized cross-over study. Neuroimage 2010, 49:1161-1170.
102. Wong D.F., Tauscher J., Gruender G. The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology 2009, 34:187-203.
103. Woodward D.J., Moises H.C., Waterhouse B.D., Yeh H.H., Cheun J.E. Modulatory actions of norepinephrine on neural circuits. Advances in Experimental Medicine and Biology 1991, 287:193-208.
104. Young M.P., Scannell J.W., Burns G.A., Blakemore C. Analysis of connectivity: Neural systems in the cerebral cortex. Reviews in the Neurosciences 1994, 5:227-249.
105. Zink C.F., Stein J.L., Kempf L., Hakimi S., Meyer-Lindenberg A. Vasopressin modulates medial prefrontal cortex-amygdala circuitry during emotion processing in humans. The Journal of Neuroscience 2010, 30:7017-7022.